GRAIL, Inc.

Healthcare

NASDAQ:GRAL · NASDAQ Global Market

Market Cap $2.74B Beta 3.16 P/E (TTM) -6.3

$63.74 +3.20%

+$1.90 today

52W Low $29.95High $118.84

Vol 0.89M · Avg 0.77M

EPS (TTM) -$9.73Medical - Diagnostics & Research

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+47.99%

Period High

$116.06

Period Low

$31.42

Latest

$63.74

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Centessa Pharmaceuticals plc

NASDAQ:CNTA

$6.17B

Apogee Therapeutics, Inc.

NASDAQ:APGE

$5.45B

Celcuity Inc.

NASDAQ:CELC

$4.19B

Xenon Pharmaceuticals Inc.

NASDAQ:XENE

$4.18B

Envista Holdings Corp

NYSE:NVST

$4.15B

Dyne Therapeutics, Inc.

NASDAQ:DYN

$3.23B

IDEAYA Biosciences, Inc.

NASDAQ:IDYA

$2.92B

Soleno Therapeutics, Inc.

SLNO

$2.76B

Ultragenyx Pharmaceutical Inc.

NASDAQ:RARE

$2.74B

Ascentage Pharma Group International

NASDAQ:AAPG

$407.64M

What is the latest GRAL filing?

The latest filing shown is 4 dated Jun 5, 2026.

How many recent filings does GRAL have?

Intrinsic Alpha currently shows 20 recent filings for GRAL.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.